Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

UBX - UNITY Biotechnology Inc Stock Price, Fair Value and News

$0.07-0.01 (-12.50%)
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

UBX Price Action

Last 7 days

28.6%

Last 30 days

-18.2%

Last 90 days

-89.0%

Trailing 12 Months

-93.6%

UBX RSI Chart

NovDec2025FebMarAprMayJunJulAug0102030405060708090

UBX Valuation

Market Cap

1.2M

Price/Earnings (Trailing)

-0.04

Price/Sales (Trailing)

5.11

Price/Free Cashflow

-0.05

UBX Price/Sales (Trailing)

202320242025050100150200250

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

UBX Fundamentals

UBX Revenue

Revenue (TTM)

236.0K

2018201920202021202201M2M3M4M5M

UBX Earnings

Earnings (TTM)

-27.5M

Earnings Growth (Yr)

-26.11%

Earnings Growth (Qtr)

13.48%

2018202020222024-100M-80M-60M-40M-20M

UBX Profitability

Return on Equity

-423.5%

Return on Assets

-90.63%

Free Cashflow Yield

-1.8K%

UBX Investor Care

Shares Dilution (1Y)

2.52%

Diluted EPS (TTM)

-1.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2018201920202021202201M2M3M4M5M
Net sales
YearQ1Q2Q3Q4
20223.6M2.5M1.4M236.0K
20210004.8M
20170001.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About UNITY Biotechnology Inc

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEhttps://unitybiotechnology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES22

UNITY Biotechnology Inc Frequently Asked Questions

What is the ticker symbol for UNITY Biotechnology Inc? What does UBX stand for in stocks?

UBX is the stock ticker symbol of UNITY Biotechnology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of UNITY Biotechnology Inc (UBX)?

As of Tue Aug 19 2025, market cap of UNITY Biotechnology Inc is 1.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UBX stock?

You can check UBX's fair value in chart for subscribers.

Is UNITY Biotechnology Inc a good stock to buy?

The fair value guage provides a quick view whether UBX is over valued or under valued. Whether UNITY Biotechnology Inc is cheap or expensive depends on the assumptions which impact UNITY Biotechnology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UBX.

What is UNITY Biotechnology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Aug 19 2025, UBX's PE ratio (Price to Earnings) is -0.04 and Price to Sales (PS) ratio is 5.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UBX PE ratio will change depending on the future growth rate expectations of investors.